A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 4, 1996, Pages 379-383

  Huber, Martin H ^a   Lippman, Scott M ^a   Benner, Steven E ^a   Shirinian, Mihran ^a   Dimery, Isaiah W ^b   Dunnington, Joel S ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Head and neck cancer; Ifosfamide

Indexed keywords

BICARBONATE; IFOSFAMIDE; MESNA;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG ACTIVITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEMATURIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MESNA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SURVIVAL RATE;

EID: 0029900793     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199608000-00012     Document Type: Article

References (13)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184-94.
2. Wolf G, Lippman SM, Laramore G, Hong WK. Head and neck cancer. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum R, eds. Cancer medicine, 3rd ed. Philadelphia: Lea & Febiger, 1993:1211-75.
3. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-63.
4. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-51.
5. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine versus cisplatin and 5-fluorouracil versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521-6.
6. Verweij J, Alexieva-Figusch J, de Boer MF, et al. Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 1988;24:795-6.
7. Cervellino JC, Araujo CE, Pirisi C, et al. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. Oncology 1991;48:89-92.
8. Kish JA, Tapazoglou E, Ensley, Al-Sarraf M. Activity of ifosfamide in recurrent head and neck cancer patients. Proc Am Assoc Cancer Res 1990;31:190a (abstract).
9. Buesa JM, Fernandez R, Esteban E, et al. Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 1991;2:151-2.
10. Martin M, Diaz-Rubio E, Gonzales-Larriba JL, et al. Ifosfamide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 1993;31:340-2.
11. Pai VR, Parikh DM, Mazumdar AT, Rao RS. Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of head and neck. Oncology 1993;50:86-91.
12. Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990;8:147- 59.
13. Meanwell CA, Blake AE, Kelly KA, et al. Prediction of ifosfamide/mesna-associated encephalopathy. Eur J Cancer Clin Oncol 1986;22:815-9.